Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Alexion’s Voydeya Earns FDA Nod as Add-on Therapy for PNH-Associated Extravascular Hemolysis

Fineline Cube Apr 2, 2024

Alexion, the rare disease unit of AstraZeneca (AZ; NASDAQ: AZN) based in the UK, has...

Company Drug

Viatris Launches Ryzumvi in the US for Rapid Reversal of Pharmacologically-Induced Pupil Dilation

Fineline Cube Apr 2, 2024

Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market,...

Company Medical Device

Huihe Healthcare’s Vispearl Microsphere Earns Marketing Approval in China for Innovative Cancer Treatment

Fineline Cube Apr 2, 2024

Shanghai-based Huihe Healthcare, a developer of interventional medical devices for structural heart diseases, has secured...

Company Drug

J&J’s Nipocalimab Fast-Tracked by FDA for Reducing FNAIT Risk in Pregnant Adults

Fineline Cube Apr 2, 2024

The US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Policy / Regulatory

US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties

Fineline Cube Apr 2, 2024

Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to...

Company

Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results

Fineline Cube Apr 2, 2024

Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its...

Company Deals

Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production

Fineline Cube Apr 2, 2024

Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...

Company

Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center

Fineline Cube Apr 2, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has...

Company Deals

China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases

Fineline Cube Apr 2, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...

Company Drug

Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam

Fineline Cube Apr 2, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Medical Device

Johnson & Johnson MedTech Launches CPX4 PLUS Tissue Expander for Breast Reconstruction in China

Fineline Cube Apr 2, 2024

Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading healthcare conglomerate in the US, has...

Company Deals

ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs

Fineline Cube Apr 2, 2024

ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a...

Company Drug

Junshi Biosciences Gets Green Light for Global Phase III Study of Tifcemalimab Combination Therapy in LS-SCLC

Fineline Cube Apr 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877), a leading biotech company based in China, has...

Policy / Regulatory

China’s National Joint Procurement Office Unveils Renewed Insulin Procurement Contracts

Fineline Cube Apr 1, 2024

The National Joint Procurement Office in China announced the upcoming renewal of drug procurement contracts...

Company Drug

FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi

Fineline Cube Apr 1, 2024

Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...

Company Drug

Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC

Fineline Cube Apr 1, 2024

Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III...

Medical Device R&D

Chinese Scientists Discover Breakthrough Biodegradable Piezoelectric Material for Medical Implants

Fineline Cube Apr 1, 2024

A team of Chinese scientists from Southeast University in Nanjing has made significant strides in...

Company Drug Legal / IP R&D

China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology

Fineline Cube Apr 1, 2024

The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9...

Company Deals Policy / Regulatory

Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries

Fineline Cube Apr 1, 2024

Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost...

Company Drug

AstraZeneca’s AKT Inhibitor Truqap Approved in Japan for HR+, HER2- Breast Cancer

Fineline Cube Apr 1, 2024

AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has registered with Japan’s Ministry of Health,...

Posts pagination

1 … 335 336 337 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.